Friday, June 3, 2011
ASCO Day 1
This will be a short post because it is late and I have an 8am session tomorrow morning.
Education Session: Survivorship Care: Whose Job is It?
Dr Paul Han (NCI) presented the initial results of the Survey of Physician Attitudes Regarding the Care of Patients. The study is not yet published. The survey asked oncologists and primary care physicians about their attitudes regarding knowledge, and practices with regard to breast and colorectal cancer follow-up care. Over 1000 oncologists and 1000 PCP's answered the survey. Not a surprise that oncologists prefer an oncologists centered plan. While 40% of the PCP's preferred a shared care plan. ( http://healthservices.cancer.gov/surveys/sparccs/)
Gynecological Poster Session and Discussion
25 posters. Where do I begin? Here are just two that might be of interest to my readers.
The Role of Bevacizumab in combination with peglated liposomal doxorubicin in patients with platinum-resistant recurrent or refractory ovarian cancers. Phase II study.
Conclusions: Bevacizumab seemed to enhance effect of Doxorubicin in platinum-resistant recurrent or refractory ovarian cancer patients. Weekly B-D warrants further clinical study in such clinical settings.
Median progression free survival was 8 months. This is an interesting combo.
A multivariate longitudinal algorithm for early detection of ovarian cancer using
This study developed an algorithm to assess the risk of Ovarian Cancer using CA-125 versus a composite index from multiple biomarkers(CA125, CA15.3, CA72.4, CA19.9, and HE4 )at 98% specificity.
Conclusions: Multiple biomarkers can be combined in a longitudinal algorithm to improve detection of early stage ovarian cancer. Additional sample sets that include independent samples of longitudinally detected cancer cases will be needed to further validate the algorithm.
More exciting research results to come.
Every Day is a Blessing! I am blessed with the opportunity to talk to so many OC researchers about their work.